1. European Medicines Agency Scientific guidelines on biosimilar medicines 2005-2013 http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000408.jsp&mid=WC0b01ac058002958c
2. Food and Drug Administration (FDA) Guidance for industry: scientific considerations in demonstrating biosimilarity to a reference product 2012 http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128
3. Australian Therapeutic Goods Administration (TGA) Evaluation of biosimilars 2013 http://www.tga.gov.au/pdf/pm-argpm-biosimilars.pdf
4. Biosimilars: it's not as simple as cost alone;Roger;J Clin Pharm Ther,2008
5. KDIGO clinical practice guideline for anemia in chronic kidney disease;Kidney Disease Improving Global Outcomes (KDIGO) Anemia Work Group;Kidney Int Suppl,2012